Author Archives: Modulight Content

About Modulight Content

Modulight wants to share high-quality scientific publications, white papers, application notes, and other articles. The articles shared are courtesy of the authoring researchers and groups and we're thankful for giving us the permission to honor their work this way. If you have something to share please drop us a line (see the contact form at Contact Us section).

Selective laser vaporization of polypropylene mesh in tissue

June 22, 2021 by Modulight Content
No comments
  Motivation for the study Surgical mesh is used to treat female stress urinary incontinence (SUI) and transvaginal pelvic organ prolapse (POP). However, erosion of this synthetic, non-absorbable mesh is a common complication and in more than half of these cases, a surgical excision of the mesh in the operating room is required. The mesh removal is technically challenging, may damage healthy adjacent tissues, and in some cases must be repeated several times. This study aims to explore the feasibility of selective laser vaporization, which Continue reading →Customer case University of North Carolina at Charlotte is a public research university founded in 1946. Department of Physics and Optical Science is dedicated on developing minimally invasive optics solutions for biomedical indications, such as tissue ablation, nerve simulation and surgical applications. Collaborations with Carolinas Medical Center at Charlotte and John Hopkins University at Maryland. Most recent research activities have focused on development of thulium fiber laser (TFL) as an alternative to the gold standard Holmium: YAG laser for lithotripsy (destruction of kidney stones), and Continue reading →

ML7710 for photoimmunotherapy against regulatory T cells in tumors

June 14, 2021 by Modulight Content
No comments
    Results Tumor growth was significantly suppressed by photoimmunotherapy, compared to control or IgG without light activation. Tumor growth suppression, as well as overall survival after photoimmunotherapy, were significantly better with F(ab´)2 fragments than with full IgG. This efficacy improvement might be related to killer T cells, which were detected in much higher numbers after photoimmunotherapy with F(ab´)2 fragments and are key cells for the generation of efficient systemic antitumor immunity.       Related Modulight products and Services   Related Publications The Effect Continue reading →Customer case The Laboratory of Molecular Theranostics is a major research section of the Molecular Imaging Program at National Cancer Institute (NCI) and is led by Dr. Hisataka Kobayashi. The groundbreaking research includes the development of imaging and theranostic probes, which can aid in cancer detection and treatment. Dr. Kobayashi has invented near-infrared photoimmunotherapy (NIR-PIT) with IRDye700DX, which is currently in FDA-designated fast-track Phase 3 trials for inoperable Head & Neck cancer. Dr. Hisataka Kobayashi M.D., PhD   Dr. Peter L. Choyke M.D., PhD   Continue reading →

Novel antimicrobial phototherapy against emerging infectious diseases

June 12, 2021 by Modulight Content
No comments
      Results PIAS-treated pathogens were effectively eradicated upon NIR illumination. The efficacy of PIAS was dependent on the NIR light dose, 50 J/cm2 eradicating all MRSA from the rat nasal tract (Figure 1). PIAS also saved all mice from fatal MRSA infections, similar to VCM+RFP antibiotics and even more effectively than VCM antibiotics alone (Figure 2). Unlike the antibiotics, PIAS acted selectively on the target pathogen and did not affect host’s normal intestinal microflora (Figure 3). Also generation of microbial resistance, common problem Continue reading →Customer case Research by: The Jikei University School of Medicine located in Tokyo, Japan and founded in 1881 is today one of the three major private medical schools in Japan. This cutting-edge study was done in close collaboration with Professor Hisataka Kobayashi’s Laboratory of Molecular Theranostics at National Cancer Institute. Modulight products: ML6500 (689 nm, 3 W)   Dr. Makoto Mitsunaga, M.D., PhD   Dr. Tadayuki Iwase, PhD   Dr. Hisataka Kobayashi, M.D., PhD Laser use: Photoimmunotherapy and photochemotherapy of cancer (pancreatic, breast, gastric) and infectious Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – May 2021

June 1, 2021 by Modulight Content
No comments
Modulight Spotlights: LASER-SHARP RESEARCH – May 2021 The renowned pioneer in photoimmunotherapy (PIT), Professor Hisataka Kobayashi, has published an outstanding article with his team at National Cancer Institute / NIH. The article is about improving the antitumor efficacy of near-infrared photoimmunotherapy (NIR-PIT) by simultaneous targeting of cancer cells and regulatory T cells in the tumor microenvironment. Read original publication   Modulight is very happy to be supporting this research. We would like to deliver our warmest congratulations to the research team!   #LaserSharpResearch  #ModulightInScience   Continue reading →

ML7710 for glioblastoma treatment

May 25, 2021 by Modulight Content
No comments
Background   Professor Stummer on glioblastoma surgeries and iPDT:   Treatment protocol 20 patients were treated. 5-ALA (Gliolan) was administered at a dosage of 20 mg/kg body weight 4 hours before anesthesia. Craniotomy was performed using FGR, with aim of maximal safe resection of the fluorescent tumor. Once there was no visible fluorescence or only tumor-infiltrated fluorescence in the eloquent areas left, PDT was performed. 1-4 cylindrical diffuser were strategically inserted depending on the size and architecture of the resection cavity and fixed to a Continue reading →Customer case Research by: University Hospital Münster provides cutting-edge medical treatments for patients all over the world. The department of neurosurgery provides a full spectrum of neurosurgical care with interdisciplinary vascular and neuro-oncological specialization. Modulight products: ML7710, ML7710i Laser use: Randomized controlled PDT trials for both newly diagnosed and recurrent glioblastoma, as well as compassionate care for terminal glioblastoma patients. Link to the study: Professor Walter Stummer, MD, PhD Research topics: Professor Stummer is a world leader in his research fields, which include vascular neurosurgery, microneurosurgery, Continue reading →

Development of heat shock protein 90-targeted PDT for inflammatory breast cancer

May 17, 2021 by Modulight Content
No comments
Motivation of the study In photodynamic therapy (PDT), systemically administered photosensitizer is activated within the tumor using focused near-infrared light, typically a laser with a wavelength matching the absorption peak of the photosensitizer. Several photosensitizers have been clinically approved for the treatment of different cancers; however, their accumulation is non-tumor exclusive which exposes healthy tissues to side effects like daylight-induced phototoxicity. A promising strategy to improve tumor selectivity is to couple photosensitizer to a tumor-targeting agent that binds to a specific antigen expressed on the Continue reading →Customer case Research by: Duke University, founded in 1924, is one of the leading and wealthiest private research universities in the USA. The most notable Duke alumni is President Richard Nixon. Research at Duke University has been awarded with several Nobel prizes in recent years for groundbreaking discoveries in biochemistry and medicine, such as G-protein coupled receptors, DNA mismatch repair, and cellular regulation of hypoxia. Modulight products: ML8500, ML7710 (665 nm, 689 nm, 750 nm) Laser use: Heat shock protein 90-targeted PDT for breast cancer Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – April 2021

May 7, 2021 by Modulight Content
No comments
Modulight Spotlights: LASER-SHARP RESEARCH – April 2021 Dr. Rhonda Kines and the team at Aura Biosciences reported promising results of their VLP (virus-like particle) photosensitizer-conjugate eliciting strong and long-lasting anti-tumor immune responses, as well as potential to combine this agent with immune checkpoint inhibitors for even improved antitumor efficacy. Read original publication   Modulight is very happy to be supporting this research. We would like to deliver our warmest congratulations to the research team!   #LaserSharpResearch #ModulightInScience   #LasersInScience #KillCancer #UvealMelanoma   Modulight products used: Continue reading →

ML7710 for fluorescence imaging: Detection of colorectal polyps in humans using c-Met targeted fluorescent peptide

May 4, 2021 by Modulight Content
No comments
Motivation for the study Polyps are small growths on the inner lining of the colon or rectum, affecting around 1 in 4 people over the age of 50. Certain types of polyps may eventually become cancerous, and colon cancer prevention relies on colonoscopy using white light to detect and remove the polyps. However, small and flat polyps are difficult to detect and frequently missed with this technique. More precise methods to detect polyps before they progress to colorectal cancer are urgently needed. GE Healthcare’s patented EMI-137 Continue reading →Customer Case Research by: GE Healthcare is a manufacturer and distributor of diagnostic imaging agents and radiopharmaceuticals, R&D collaborations with Leiden University MC for early detection of colorectal tumors. Modulight products: ML7710 series clinical laser system (635 nm, 3 W) Laser use: Clinical single-wavelength laser device used for exciting novel fluorescence probe used to detect colorectal polyps. Link to the study: Dr. James Hardwick, Professor of gastroenterology & hepatology Research topics: Professor Hardwick’s research has contributed to many key improvements in the detection and treatment of colorectal Continue reading →

Vascular-targeted phototherapy study for prostate cancer

April 28, 2021 by Modulight Content
No comments
  Study protocol         Related Modulight products and Services ML7710 – Laser device suited for pre-clinical and clinical applications »      Related Publications WST11 Vascular Targeted Photodynamic Therapy Effect Monitoring by Multispectral Optoacoustic Tomography (MSOT) in Mice Volker Neuschmelting, Kwanghee Kim, Jaber Malekzadeh-Najafabadi, Sylvia Jebiwott, Jaya Prakash, Avigdor Scherz, Jonathan A Coleman, Moritz F Kircher, Vasilis Ntziachristos Theranostics, 2018, 8 (3)   High-resolution optoacoustic imaging of tissue responses to vascular-targeted therapies Katja Haedicke, Lilach Agemy, Murad Omar, Andrei Berezhnoi, Sheryl Roberts, Camila Longo-Machado, Magdalena Skubal, Karan Nagar, Hsiao-Ting Hsu, Kwanghee Kim, Thomas Reiner, Jonathan Coleman, Vasilis Ntziachristos, Avigdor Scherz, Jan Grimm Nat Biomed Continue reading →Basic Info of the Study Research by: Memorial Sloan Kettering Cancer Center is one of the world’s premier cancer centers, collaborating with Weizmann Institute of Science research group. Modulight products: ML7710 (753 nm) Laser use: Study effects of vascular-targeted phototherapy in xenograft models Link to the study: Dr. Kwanghee Kim Dr. Avigdor Scherz   Vascular-targeted phototherapy Vascular-targeted phototherapy (VTP) was developed by Avigdor Scherz (Weizmann Institute of Science), and it is now owned by Steba Biotech. VTP agent Tookad was clinically approved for low-risk prostate cancer Continue reading →

In vitro illumination using ML8500: osmium-based anticancer photosensitizer with highest hypoxic activity reported to date

March 26, 2021 by Modulight Content
No comments
  Study protocol to determine wavelength, fluence, and irradiance activities of Os-4T:   Key observations Illumination parameters significantly affected the phototoxicity of Os-4T. The green light (525 nm) was more effective than the red light (630 nm) at lower fluences, while the maximal potency was achieved at both wavelengths when using fluences higher than 100 J/cm2. Irradiance affected the potency with both the red and the green light that were more effective when lower irradiances were used.   Graphs from the original publication. Open-access content Continue reading →Basic Info of the Study Research by: University of Texas at Arlington, US. One of the leading groups in photoactive drug discovery. Developed first clinical-level rubidium-based PS (TLD-1433), now in Theralase-sponsored Phase 2 trials for bladder cancer. Modulight products: ML8500 (445 nm, 525 nm, 630 nm, 753 nm, 810 nm) Laser use: Photoactive drug discovery Link to the study: Dr. Sherri McFarland (see her referral of Modulight) Research topics: Medicinal inorganic chemistry and drug discovery. Special interest in the synthesis of novel transition metal complexes and Continue reading →